These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6118115)

  • 1. Thyrotrophin-binding inhibitory immunoglobulins and HLA-DRW3-two prognostic factors in Graves' disease.
    Teng CS; Yeung RT; Kawa A; Nakamura S; Nomoto K; Arima N; Koreeda N; Tsuji K; Ho PW
    Aust N Z J Med; 1981 Aug; 11(4):383-5. PubMed ID: 6118115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
    Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease.
    Cho BY; Shong MH; Yi KH; Lee HK; Koh CS; Min HK
    Clin Endocrinol (Oxf); 1992 Jun; 36(6):585-90. PubMed ID: 1358483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W; Man N; Li YS; Shan ZY; Teng WP
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of parallel measurements of thyrotropin binding inhibiting immunoglobulins (TBII) and thyroid adenylate cyclase stimulating antibodies (TSAb) in Graves' disease after longterm antithyroid treatment.
    Bliddal H; Bech K; Siersbaek-Nielsen K; Friis T
    J Endocrinol Invest; 1983 Aug; 6(4):259-62. PubMed ID: 6139399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyrotrophin binding inhibiting immunoglobulins in Graves' disease before, during and after antithyroid therapy, and its relation to long-acting thyroid stimulator.
    Docter R; Bos G; Visser TJ; Hennemann G
    Clin Endocrinol (Oxf); 1980 Feb; 12(2):143-53. PubMed ID: 6105023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demonstration of anti-TSH antibody in TSH binding inhibitory immunoglobulin-positive sera of patients with Graves' disease.
    Ochi Y; Hamazu M; Kajita Y; Nagata A
    Clin Endocrinol (Oxf); 2002 Mar; 56(3):405-12. PubMed ID: 11940054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
    Tamaki H; Amino N; Aozasa M; Mori M; Tanizawa O; Miyai K
    J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of outcome in Graves' disease after carbimazole treatment.
    Weetman AP; Ratanachaiyavong S; Middleton GW; Love W; John R; Owen GM; Darke C; Lazarus JH; Hall R; McGregor AM
    Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.
    Kawai K; Tamai H; Matsubayashi S; Mukuta T; Morita T; Kubo C; Kuma K
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):551-6. PubMed ID: 8548939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of radioiodine on stimulatory activity of Graves' immunoglobulins.
    Atkinson S; McGregor AM; Kendall-Taylor P; Peterson MM; Smith BR
    Clin Endocrinol (Oxf); 1982 Jun; 16(6):537-43. PubMed ID: 6125279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct and quantitative measurement by immunoprecipitation assay of anti-thyrotrophin receptor antibodies in sera of patients with Graves' disease.
    de Bruin TW; van der Heide D; Querido A; Krol MC
    Clin Endocrinol (Oxf); 1984 Feb; 20(2):143-51. PubMed ID: 6325045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.
    Hörmann R; Saller B; Müller R; Mann K
    Klin Wochenschr; 1985 Dec; 63(24):1247-52. PubMed ID: 2868149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of HLA types and clinical findings in Japanese patients with hyperthyroid Graves' disease: evidence indicating the existence of four subpopulations.
    Inoue D; Sato K; Enomoto T; Sugawa H; Maeda M; Inoko H; Tsuji K; Mori T; Imura H
    Clin Endocrinol (Oxf); 1992 Jan; 36(1):75-82. PubMed ID: 1559302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of TSH receptor antibody by 'natural in vivo human assay' in neonates born to mothers with Graves' disease.
    Tamaki H; Amino N; Iwatani Y; Tachi J; Kimura M; Mitsuda N; Ichihara K; Tanizawa O; Miyai K
    Clin Endocrinol (Oxf); 1989 May; 30(5):493-503. PubMed ID: 2575017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease.
    Aizawa Y; Yoshida K; Kaise N; Kaise K; Fukazawa H; Kiso Y; Mori K; Sayama N; Kikuchi K; Abe K
    Clin Endocrinol (Oxf); 1995 May; 42(5):517-22. PubMed ID: 7621571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in thyrotropin binding inhibiting immunoglobulins (TBII) in sera of patients with Graves' disease at the time of relapse or exacerbation.
    Uchimura H; Akimoto N; Mitsuhashi T; Kubota K; Kuzuya N; Imai Y; Ikeda H; Matsuzaki F; Kumagai LF
    J Endocrinol Invest; 1986 Feb; 9(1):37-42. PubMed ID: 2422245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.